Mark Versavel Net Worth

Mark Versavel biography

Dr. Mark Versavel M.D. Ph.D. serves as Chief Medical Officer of the Company. Prior to that, he served as Private NeuroBo's Chief Medical Officer since February 2018. Dr. Versavel has also been the founder and owner of vZenium LLC, providing consulting services to life sciences companies engaged in central nervous system clinical development, since March 2014 and, since March 2019, has served as the Chief Medical Officer of Cavion, Inc., a privately-held, clinical stage biotechnology company developing therapeutics for neurological diseases. From May 2014 until December 2018, Dr. Versavel also provided advisory services to life sciences companies through the privately-held staffing agency, Atrium Staffing. Dr. Versavel also served as the Chief Medical Officer of Alzheon, Inc., a privately-held, clinical-stage biopharmaceutical company developing medicines for patients with Alzheimer's disease, from September 2013 until September 2015. From March 2014 until November 2015, Dr. Versavel was also a principal of Akta Pharmaceutical Development, an international, privately-held company engaged in providing consulting services for biopharmaceutical companies. Dr. Versavel has over 25 years of clinical development experience in neuropathic pain and multiple neurology and psychiatry indications across the areas of clinical pharmacology, early and late phase clinical trials, and in the support of marketed products in the public companies Bayer AG, Schering AG, Parke Davis, Pfizer and Sunovion. Dr. Versavel received his M.D. from the University of Antwerp, his Ph.D. in clinical pharmacology from the Humboldt University of Berlin and his M.B.A. from the University of Michigan.

How old is Mark Versavel?

Mark Versavel is 61, he's been the Chief Medical Officer of NeuroBo Pharmaceuticals Inc since 2019. There are 2 older and 8 younger executives at NeuroBo Pharmaceuticals Inc. The oldest executive at NeuroBo Pharmaceuticals Inc is Michael Salsbury, 70, who is the Independent Director.

What's Mark Versavel's mailing address?

Mark's mailing address filed with the SEC is C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON, MA, 02115.

Insiders trading at NeuroBo Pharmaceuticals Inc

Over the last 5 years, insiders at NeuroBo Pharmaceuticals Inc have traded over $0 worth of NeuroBo Pharmaceuticals Inc stock and bought 2,544,530 units worth $7,964,379 . The most active insiders traders include St Co., Ltd Dong A, Tae Heum Jeong и Steven R. Ph.D. Gullans. On average, NeuroBo Pharmaceuticals Inc executives and independent directors trade stock every 0 days with the average trade being worth of $9,541,988. The most recent stock trade was executed by St Co., Ltd Dong A on 23 June 2024, trading 2,544,530 units of NRBO stock currently worth $7,964,379.

What does NeuroBo Pharmaceuticals Inc do?

neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.

NeuroBo Pharmaceuticals Inc executives and stock owners

NeuroBo Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Dr. Ben Gil Price M.D.,
  CEO & Pres
• Nicola Shannon,
  Vice President - Clinical Operations
• Akash Bakshi,
  Sr. VP & COO
• Michael Miller,
  Investor Relations
• Douglas Swirsky,
  Independent Director
• Michael Salsbury,
  Independent Director
• Jeong Gyun Oh,
  Independent Director
• Tae Heum Jeong,
  Independent Director
• Jason Groves,
  Independent Director
• Mark Versavel,
  Chief Medical Officer
• jeong Gu Kang,
  President, Chief Executive Officer, Interim Chief Financial Officer, Secretary, Treasurer and Director
• Na Yeon Kim,
  Independent Chairman of the Board
• Frank Kondrad,
  VP of Corp. & Bus. Devel.
• Dr. Matthew Bardin BCPS, Pharm.D.,
  Sr. VP of Operations
• Dr. Nadja Mannowetz Ph.D.,
  Sr. VP
• Dr. Andrew Bartynski Ph.D.,
  Sr. VP
• Dr. Gil Price M.D.,
  CEO, Pres & Chief Medical Officer
• Dr. Jeong Gu Kang Ph.D.,
  Pres, CEO, Sec., Interim CFO, Treasurer & Director
• St Co., Ltd Dong A,
  
• Mark A Glickman,
  Director
• Akash Bakshi,
  SVP and COO
• Steven R. Ph.D. Gullans,
  Director
• James Patrick Tursi,
  Director
• Ben Gil Price,
  CEO and President
• D Gordon Strickland,
  Director
• Richard Kang,
  Director
• Inc.E&Healthcare Investment...,
  
• Hyung Heon Kim,
  CEO & President
• Marshall H Woodworth,
  Chief Financial Officer